Table 5. Pooled risk ratio of sustained virological response at week 12 after the end of treatment between sofosbuvir plus ledipasvir with ribavirin and sofosbuvir plus ledipasvir.
| Author | Year | SOF plus LDV with RBV | SOF plus LDV | RR (95% CI) | ||
|---|---|---|---|---|---|---|
| Response | Non-response | Response | Non-response | |||
| Afdhal [18] | 2014 | 426 | 8 | 423 | 8 | 1.00 (0.98, 1.02) |
| Kowdley [17] | 2014 | 201 | 15 | 408 | 23 | 0.98 (0.94, 1.02) |
| Lawitz [19] | 2014 | 21 | 0 | 37 | 2 | 1.04 (0.94, 1.15) |
| Mizokami [23] | 2015 | 80 | 3 | 83 | 0 | 0.96 (0.92, 1.01) |
| Pooled RR | 0.99 (0.97, 1.01) | |||||
CI, confidence interval; LDV, ledipasvir; RR, risk ratio; RBV, ribavirin; SOF, sofosbuvir; SVR24, sustained virological response at week 24 after the end of treatment.